The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 7 rounds in the feed, most often at Series B and in Biotech.
Corporate venture armamgen.comRounds from 2022-07-20 to ~ 2026-10-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Soufflé Therapeutics A leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives | Series B Verified against 1 of 29 sources | $135M | ~ 2026-10-10 | [ PART ] |
Arboretum LifeSciences A molecular information company | Series A |
| $30M |
| 2026-10-05 |
| [ LEAD ] |
BigHat Biosciences A clinical-stage, AI-driven protein therapeutics platform company | Series C Verified against 4 of 28 sources | $75M | 2026-09-23 | [ PART ] |
AAVantgarde AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $141M | 2025-11-03 | [ PART ] |
Quantinuum Quantinuum sells quantum computing products and solutions to businesses and developers for advanced computing applications. | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $600M | 2025-09-04 | [ PART ] |
Quantinuum Quantinuum sells quantum computing products and solutions to businesses and developers for advanced computing applications. | Equity fundraise Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $300M | 2024-01-16 | [ PART ] |
BigHat Biosciences A clinical-stage, AI-driven protein therapeutics platform company | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $75M | 2022-07-20 | [ PART ] |